Abstract:The current global COVID-19 pandemic is caused by beta coronavirus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which already infected over 10 million and caused 500 thousand deaths by June 2020. Overproduction of cytokines triggered by COVID-19 infection, known as "cytokine storm", is a highly risk factor associated with disease severity. However, how COVID-19 infection induce cytokine storm is still largely unknown. Accumulating in vitro and in vivo evidence suggests that gut is also susceptible to COVID19 infection: Human intestinal organoids, an in vitro model which mimic the specific cell type and spatial structure of the intestine, were susceptible to SARS-CoV2 infection; A significant fraction of patients reported gut symptoms; Viral RNA may persist for more than 30 days and infectious virus could be isolated in fecal samples. The gastrointestinal tract is the primary site of interaction between the host immune system with symbiotic and pathogenic microorganisms. The bacteria resident in our gastrointestinal tract, known as gut microbiota, is important to maintain the homeostasis of our immune system. While imbalance of gut microbiota, or dysbiosis, is associated with multiple inflammation diseases5. It's possible that SARS-CoV-2 infection may lead to alternation of gut microbiota thus worsen the host symptom. IL-18 is a proinflammatory cytokine produced multiple enteric cells, including intestinal epithelial cells (IECs), immune cells as well as enteric nervous system, and was shown to increase in the serum of COVID-19 patients. Immunoglobin A (IgA) is mainly produced in the mucosal surfaces, in humans 40-60mg kg-1 day-1 than all other immunoglobulin isotypes combined, and at least 80% of all plasma cells are located in the intestinal lamina propria. Recent study showed that SARS-CoV-2 specific IgA in the serum is positively correlate with the disease severity in COVID-19 patients11. Here we investigated the alterations of microbiota in COVID-19 patients, and its correlation with inflammatory factor IL-18 and SARS-CoV2 specific IgA. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by a grant from the National Key R&D Program of China (2018YFA0508000) (SZ), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29030101) (SZ), the National Natural Science Foundation of China (81822021, 91842105, 31770990, 81821001) (SZ), and the Fundamental Research Funds for the Central Universities (WK2070000159) (SZ). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This is an observational cohort study. This study is part of the project of "Construction of a bio-information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui" (ChiCTR2000030331). This study was approved by the institutional board of the First Affiliated Hospital of University of Science and Technology of China (2020-XG(H)-009). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data are available upon request.

Post-infection functional gastrointestinal disorders following coronavirus disease-19: a prospective follow-up cohort study

Post‐infection functional gastrointestinal disorders following coronavirus disease‐19: A case–control study

Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms

Gastrointestinal manifestations in symptomatic Coronavirus disease - 19 patients and its relevance in predicting severity and outcome

Alterations of the Gut Microbiota in Patients with Coronavirus Disease 2019 or H1N1 Influenza.

Epidemiological, Clinical and Virological Characteristics of 74 Cases of Coronavirus-Infected Disease 2019 (COVID-19) with Gastrointestinal Symptoms

Gastrointestinal Sequelae of COVID-19: Investigating Post-Infection Complications—A Systematic Review

S233 Gastrointestinal Sequelae of COVID-19: Investigating Post-Infection Complications

Altered Intestinal Microbiota with Increased Abundance of Prevotella is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome.

Gastrointestinal Consequences of Discharged COVID-19 Patients: A Multicenter Cohort Study

P899 Inflammatory Bowel Disease Patients Show More Recognizable Digestive Symptoms of COVID-19: A Questionnaire Study

Intestinal inflammation and permeability in patients recovered from SARS-CoV-2 infection.

Analysis of the intestinal microbiota in COVID 19 patients and its correlation with the inflammatory factor IL 18 and SARS CoV 2 specific IgA

The Prevalence of Irritable Bowel Syndrome after Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Their Association: A Systematic Review and Meta-Analysis of Observational Studies

COVID-19 and the digestive system: A comprehensive review

Symptomatology and microbiology of the gastrointestinal tract in post‐COVID conditions

Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19

Development and management of gastrointestinal symptoms in long-term COVID-19

Impact of mechanical barrier damage and interleukin-17 on symptoms in patients with post-infectious irritable bowel syndrome

Gastrointestinal symptoms of long COVID-19 related to the ectopic colonization of specific bacteria that move between the upper and lower alimentary tract and alterations in serum metabolites

Gut microbiota in COVID-19: new insights from inside